Introduction
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer among males and females ([@b1-ijmm-42-01-0368]). Surgical resection is an effective treatment for early-stage CRC, while chemotherapy is the main treatment for patients with advanced CRC. In recent years, effective observation strategies following curative treatment for CRC have helped improve the overall survival (OS) of patients, and a number of CRC patients are eligible for such curative treatment ([@b2-ijmm-42-01-0368]--[@b4-ijmm-42-01-0368]). The fecal immunochemical test (FIT), a simple and easy method, has been widely used in CRC screening programs ([@b5-ijmm-42-01-0368]--[@b7-ijmm-42-01-0368]). However, the 5-year survival rate significantly declines when cancer cells spread to adjacent organs or lymph nodes ([@b8-ijmm-42-01-0368]--[@b10-ijmm-42-01-0368]). Due to the genetic heterogeneity of CRC, studying the tumor initiation and progression at a molecular level can help to uncover the pathogenesis of CRC. During the past decades, researchers have identified various important gene biomarkers, including tumor oncogenes (such as KRAS, BRAF and PIK3CA) and suppressor genes (such as A00PC, TP53 and PTEN). These genes are critical for the genesis and development of CRC, demonstrating the potential clinical significance for the treatment of CRC ([@b11-ijmm-42-01-0368],[@b12-ijmm-42-01-0368]).

As accumulating evidence has suggested inflammation is a tumor-promoting hallmark that contributes to tumor initiation and progression ([@b13-ijmm-42-01-0368]). CRC has been reported to be associated with chronic bowel inflammation ([@b14-ijmm-42-01-0368]--[@b16-ijmm-42-01-0368]), indicating the crucial roles of inflammatory genes in the tumorigenesis and development of CRC. Additionally, a number of studies have reported the importance of single inflammatory genes in CRC. For instance, Cho *et al* ([@b17-ijmm-42-01-0368]) revealed that genetic variation in *PPARGC1A* affected the role of diet-associated inflammation in CRC. Furthermore, Li *et al* ([@b18-ijmm-42-01-0368]) identified that the inflammatory molecule PSGL-1, involved in the nuclear factor-κB signaling pathway, can promote CRC growth by activating macrophages. However, the study of inflammatory genes in the context of functional interaction networks remains unclear, which drives us to predict novel network-based inflammation-associated signatures. In addition, a variety of public gene expression profiling datasets and protein-protein interactions (PPIs) make it possible to study the network of inflammatory genes further in order to identify novel biomarkers for CRC. Chuang *et al* ([@b19-ijmm-42-01-0368]) used a protein-network-based approach to identify biomarkers as sub-networks. Similarly, by developing a network-based method, Li *et al* ([@b20-ijmm-42-01-0368]) identified cancer prognostic biomarkers based on microarray and network datasets.

The present study aimed to investigate how inflammatory genes functioned in the context of inflammation-associated networks and their prognostic value in CRC, and two inflammation-associated networks were constructed. Topological properties were used to measure the network structure, as well as the crucial positions of the inflammatory and inflammation-associated genes in the two networks in CRC. Furthermore, a 14-gene module was identified in the IRDN, and notably, all 14 genes in this module were inflammatory genes. The prognostic significance of this module comprising 14 inflammatory genes was validated by three independent datasets. The current study findings highlighted the novel role of the inflammation-associated network in CRC, providing an insight into the inflammation-mediated mechanisms involved in this disease.

Materials and methods
=====================

Data resources
--------------

CRC patients with whole-genome gene expression profiles (Affymetrix Human Exon 1.0 ST Array) were downloaded from the publicly available Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). A total of 90 specimens were included in the study of network construction, including 77 tumor and 13 normal samples from the study by Sveen *et al* ([@b21-ijmm-42-01-0368]) with the accession number GSE24550 ([Table I](#tI-ijmm-42-01-0368){ref-type="table"}). In addition, another three GEO datasets, namely GSE24549, GSE24551 and GSE103479 ([Table I](#tI-ijmm-42-01-0368){ref-type="table"}) ([@b22-ijmm-42-01-0368],[@b23-ijmm-42-01-0368]), were downloaded for validation analyses. The GSE24550 dataset, which is a subset of GSE24551, was selected as a training set. Furthermore, CRC patients\' stage information was obtained for these four datasets and other clinical features (age, gender, BRAF/KRAS/P53 mutations) for the GSE103479 dataset.

Gene Ontology (GO) ([@b24-ijmm-42-01-0368]) terms associated with the inflammatory response were obtained from the study by Plaisier *et al* ([@b25-ijmm-42-01-0368]). The genes annotated to these inflammation-associated GO terms were obtained from the AmiGO2 tool ([@b26-ijmm-42-01-0368]) of the GO Consortium. Finally, 909 inflammatory genes were collected for subsequent analyses.

The protein-protein interaction (PPI) data were downloaded from the Human Protein Reference Database (HPRD) release 9 (<http://www.hprd.org/>) ([@b27-ijmm-42-01-0368]). It contained \>42,000 manually curated interactions between 9,826 human genes.

Differentially expressed gene (DEG) analysis
--------------------------------------------

The raw array data (.CEL files) of samples in the four GEO datasets were uniformly pre-processed using the Robust Multichip Average algorithm for background correction, quantified normalization and log~2~-transformation ([@b28-ijmm-42-01-0368]). To account for the heterogeneity of multiple microarray datasets in systematic measurements, each dataset was standardized independently by the Z-score transformation to balance the expression intensities of each probe ([@b29-ijmm-42-01-0368]). DEGs were identified using a two-tailed t-test for GSE24550. Genes with a false discovery rate (FDR) cutoff value of 0.001 following adjustment of the P-value were considered as DEGs. The unsupervised hierarchical clustering of CRC samples and DEGs was performed with R software (<https://www.r-project.org/>) using the Euclidean distance and complete linkage method.

Network construction and analysis
---------------------------------

Cytoscape version 3.2.0 ([@b30-ijmm-42-01-0368]) was used for the construction of the networks in the current study. The first network was established according to the following procedure: The human PPI network was initially downloaded from the HPRD, all the inflammatory gene symbols were acquired from AmiGO2, and all the inflammatory genes were mapped to the human PPI network. Subsequently, a sub-network including inflammatory genes and their direct interacting genes in the network (referred to as inflammatory neighbor genes) was selected. Finally, the sub-network was termed the inflammation-related neighbor network (IRNN). The second sub-network was constructed as follows: DEGs of CRC were mapped to IRNN, and then a sub-network including DEGs and their direct interacting genes in the IRNN (referred to as DEG neighbor genes) was selected. The second sub-network was termed the inflammation-related driver network (IRDN) for subsequent analyses.

In order to explore the topological properties of the inflammatory genes in the IRNN and IRDN, the following features were analyzed: Degree, betweenness centrality (BC) and closeness centrality (CC), which were used to decipher the structure of the sub-networks and to identify specific vital molecules. Degree was used to determine the number of neighbors for each node. BC represented the key role of a node in communication and information diffusion ([@b31-ijmm-42-01-0368]). Node CC measured the local cohesiveness, such as how close a node is to other nodes. The IRNN and IRDN visualization and topological properties were analyzed using Cytoscape version 3.2.0 and the R software.

Identifying prognostic modules in IRDN
--------------------------------------

The cFinder algorithm ([@b32-ijmm-42-01-0368]) is a classic method used to identify modules from a network, in which the identification and visualization of overlapping dense groups of nodes was conducted using the Clique Percolation Method ([@b33-ijmm-42-01-0368]). Modules were identified through this method in the present study by locating the k-clique percolation clusters of the network. A k-clique percolation cluster includes the following two parts: i) all nodes that can be reached via chains of adjacent k-cliques from each other; and ii) the links in these cliques. Larger values of k correspond to a higher stringency during the identification of dense groups and provide smaller groups with a higher density of links inside them.

Functional enrichment analysis
------------------------------

Genes were functionally annotated to identify enriched pathways based on DAVID Bioinformatics Resources (version 6.7; <http://david.abcc.ncifcrf.gov/>) ([@b34-ijmm-42-01-0368]). The DAVID enrichment analyses were limited to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and GO-FAT biological process (BP) terms, with the whole human genome as background. Functional categories were visualized and clustered using the Enrichment Map plugin ([@b35-ijmm-42-01-0368]) in Cytoscape version 3.2.0.

Survival analysis
-----------------

In order to validate whether the module identified in the aforementioned step was associated with CRC patient survival, the expression of mRNAs in the module was extracted. Next, Cox proportional hazard analysis was used to obtain the regression coefficient of each gene associated with patient survival. The classifier was built as the linear combination of the gene expression values of the selected genes using the standardized Cox regression coefficient as the weight. A risk score formula for each patient was established by including the expression values of each selected gene weighted by their estimated regression coefficients in the univariate Cox regression analysis. As a result, patients were divided into the high-risk and low-risk groups ([@b36-ijmm-42-01-0368]) using the median value of the risk score as the threshold. Kaplan-Meier survival plots and log-rank tests were used to assess the differences in disease-free survivalb (DFS) duration between the high-risk and low-risk patients. In addition, the sensitivity and specificity of the module for survival prediction was evaluated using receiver operating characteristic (ROC) curve analysis, and the area under the ROC curve (AUC) was calculated.

Statistical analysis
--------------------

In the construction of IRNN, two-tailed t-test and FDR adjustion were used to identify CRC-related DEGs. Furthermore, univariate and multivariate Cox regression analyses and log-rank test were applied in survival analysis.

Results
=======

Inflammatory genes serve a crucial role in CRC
----------------------------------------------

Based on the PPI network, an IRNN was constructed, which included 9,293 interactions of 3,526 nodes (575 inflammatory genes and their 2,928 neighbors; [Fig. 1A](#f1-ijmm-42-01-0368){ref-type="fig"}). In the IRNN, there were 17 inflammatory genes (such as CCL19, CD36, COL1A1, CXCL13, ITK and KIT) that were DEGs, as well as 558 inflammatory genes (including PRKACA, TRAF2, PIK3R1, SHC1, PTPN11, LCK and GRB2) that were associated with the DEGs.

In order to explore the construction and features of the IRNN, network topology analysis was performed. As observed, the global degree distribution of nodes in the IRNN closely followed the power law distribution ([Fig. 1B](#f1-ijmm-42-01-0368){ref-type="fig"}). Furthermore, the inflammatory genes, DEGs and other nodes exhibited a small-world network organization ([Fig. 1B](#f1-ijmm-42-01-0368){ref-type="fig"}), which suggested that the IRNN constructed was biologically significant.

Inflammatory genes serve critical hub roles by interacting with DEGs in CRC
---------------------------------------------------------------------------

To further explore the role of inflammatory genes in the IRNN, analysis of the topological features, including the degree, CCs and BCs, was performed. The results demonstrated that inflammatory genes in the IRNN had a higher degree, CCs and BCs compared with their neighbors that were non-inflammatory genes in the IRNN (P\<2.2×10^−16^ for degree; P=1.15×10^−14^ for CC; P\<2.2×10^−16^ for BC; Wilcoxon rank sum test; [Fig. 2A--C](#f2-ijmm-42-01-0368){ref-type="fig"}, respectively), indicating that inflammatory genes were central within the IRNN.

As observed earlier, inflammatory genes tended to be located in the hub node positions in the IRNN; therefore, the present study further deciphered these inflammatory hub genes in detail. Previously, hubs were typically defined as the top 10--20% of nodes in the networks based on their degree ([@b37-ijmm-42-01-0368],[@b38-ijmm-42-01-0368]). Thus, the top 10% of nodes were selected as the hub components based on the highest degrees, identifying a total of 347 hub nodes. Furthermore, all the hub nodes were found to belong to inflammatory genes with a significantly higher BC compared with that of all the inflammatory genes in the IRNN (P\<2.2×10^−16^; [Fig. 2D](#f2-ijmm-42-01-0368){ref-type="fig"}). These findings indicated that certain inflammatory genes had critical hub roles in the IRNN. However, the BCs of hub genes were higher in comparison with those of DEGs (P\<2.2×10^−16^; [Fig. 2E](#f2-ijmm-42-01-0368){ref-type="fig"}), indicating that these DEGs served critical roles in the communication with their neighboring nodes in the IRNN. The KIT gene, a DEG in the IRNN sub-network, encodes c-kit tyrosine kinase whose inhibitor STI571 reportedly exhibits a substantial therapeutic activity in patients with CRC ([@b39-ijmm-42-01-0368]). KIT, which interacted with two hub inflammatory genes (FYN and SRC) in the IRNN, is inhibited by dasatinib, which is studied in solid tumors such as CRC by combining with capecitabine and oxaliplatin ([@b40-ijmm-42-01-0368]). These observations demonstrated that hub inflammatory gene-associated DEGs were more likely to be essential for CRC development and progression.

The top six inflammatory genes (EP300, SRC, CREBBP, GRB2, MAPK1 and FYN) in terms of the node degree had a direct connection in the network, indicating that inflammatory genes function as hubs in the sub-networks ([Fig. 3](#f3-ijmm-42-01-0368){ref-type="fig"}).

Inflammatory genes directly interact with CRC-associated DEGs
-------------------------------------------------------------

To further explore the association between inflammatory genes and DEGs, a network termed IRDN was constructed, which included DEGs and their neighbors extracted from the IRNN ([Fig. 4A](#f4-ijmm-42-01-0368){ref-type="fig"}). The IRDN included 209 genes, of which 83 were DEGs. In total, 121 of the genes in IRDN were inflammatory genes, and 17 of these were also DEGs. Similar to the nodes in IRNN, the nodes in the IRDN also exhibited a small-world network organization ([Fig. 4B](#f4-ijmm-42-01-0368){ref-type="fig"}), which suggested that the IRDN was also biologically significant. These results suggested that the IRDN obtained from IRNN may serve a crucial role in the biogenesis of CRC.

A functional enrichment analysis of all genes in IRDN was also performed based on GO and KEGG pathway analyses. IRDN mRNAs were enriched in 200 GO_BP_FAT terms (FDR\<0.001) mainly in eight functional clusters, including cell adhesion, cell communication, cell activation, immune response, cell death and apoptosis, signal transduction, response to stimulus and phosphorylation ([Fig. 5A](#f5-ijmm-42-01-0368){ref-type="fig"}). In addition, 25 KEGG pathways (FDR\<0.01) were involved, including cancer, focal adhesion and several signaling pathways ([Fig. 5B](#f5-ijmm-42-01-0368){ref-type="fig"}). All enriched signaling pathways, including ErbB, Jak-STAT, MAPK and NOD-like receptor signaling, are known to be contributors to CRC pathogenesis ([@b41-ijmm-42-01-0368]--[@b44-ijmm-42-01-0368]).

Identifying inflammatory network-based biomarkers in CRC
--------------------------------------------------------

Using the cFindeR software, two inflammation-associated modules in IRDN with k-clique ≥5 were identified. Next, the study investigated whether these two inflammatory gene-associated modules have a prognostic potential in CRC. Using the training dataset GSE24550 ([Table II](#tII-ijmm-42-01-0368){ref-type="table"}), a risk-score formula was created according to the expression of these two module genes to generate DFS prediction. Using the median risk score of the training series as the cutoff point, the risk scores of the module genes were calculated for each patient and then patients were ranked according to their risk score. The patients were grouped into the high-risk or low-risk categories using the median risk score of the training series as the cutoff point. As a result, the module comprising 14 inflammatory genes with k-clique=6 ([Fig. 6A](#f6-ijmm-42-01-0368){ref-type="fig"}) was able to divide patients into the high- and low-risk groups with a significantly reduced DFS observed in the high-risk group (log-rank test, P=1.80×10^−4^; [Fig. 6B](#f6-ijmm-42-01-0368){ref-type="fig"}). Additionally, the distribution of gene risk score and the survival status of the training dataset are shown in [Fig. 6C](#f6-ijmm-42-01-0368){ref-type="fig"}. Furthermore, a time-dependent ROC curve analysis was performed to evaluate the sensitivity and specificity for module survival prediction. The module achieved an AUC value of 0.791 ([Fig. 6D](#f6-ijmm-42-01-0368){ref-type="fig"}), suggesting a substantially effective performance.

Validating the prognostic potential of 14-inflammatory-gene-module in independent datasets
------------------------------------------------------------------------------------------

To validate the prognostic performance of the 14-inflammatory-gene-module, three independent GEO datasets were used in the subsequent analyses ([Table II](#tII-ijmm-42-01-0368){ref-type="table"}). Using the same risk score formula as earlier, patients in each dataset were classified into the high-risk and low-risk groups using the median score of the training series as the cutoff point. Consistent with the previous findings, patients in the high-risk group had significantly shorter median DFS or OS when compared with those in the low-risk group (GSE24549 patients: Log-rank test P=1.99×10^−2^, [Fig. 7A](#f7-ijmm-42-01-0368){ref-type="fig"}; GSE24551 patients: Log-rank test P=8.27×10^−4^, [Fig. 7B](#f7-ijmm-42-01-0368){ref-type="fig"}; GSE103479 patients: Log-rank test P=3.41×10^−2^, [Fig. 7C](#f7-ijmm-42-01-0368){ref-type="fig"}). Similarly, the distribution of gene risk scores and the survival statuses of the three datasets are displayed in [Fig. 7D--F](#f7-ijmm-42-01-0368){ref-type="fig"}. Patients with high-risk scores tended to present poorer clinical outcomes compared with patients with low-risk scores. The time-dependent ROC curve analysis was performed to evaluate the sensitivity and specificity for module survival prediction in these three GEO datasets. The module achieved AUC values of 0.634, 0.697 and 0.607 in the GSE24549, GSE24551 and GSE103479 datasets, respectively, indicating that high prediction performance ([Fig. 7G--I](#f7-ijmm-42-01-0368){ref-type="fig"}).

Subsequent to further adjusting for other clinical markers univariate analysis indicated that the 14-inflammatory-gene-module was significantly associated with the DFS of CRC patients from the GSE24549 \[hazard ratio (HR)=1.28; 95% confidence interval (CI)=0.99--1.66; P=0.052\] and GSE24551 datasets (HR=1.88; 95% CI=1.42--2.47; P\<0.001), as well as the OS of patients from the GSE103479 dataset (HR=2.13; 95% CI=1.24--3.64; P=0.006), as an independent risk factor ([Table III](#tIII-ijmm-42-01-0368){ref-type="table"}). Subsequently, when multivariate analysis was performed to investigate the independence of the module to other clinical factors, the module was not independent of the stage in GSE24549 (HR=1.93; 95% CI=1.05--3.56; P=0.034), and GSE103479 (HR=2.37; 95% CI=1.34--4.21; P=0.003) datasets ([Table III](#tIII-ijmm-42-01-0368){ref-type="table"}). Furthermore, data stratification analysis on GSE24549 patients indicated that the module was independent of stage (P=1.50×10^−2^ for stage II group; P=1.51×10^−2^ for stage III group; [Fig. 8A and B](#f8-ijmm-42-01-0368){ref-type="fig"}), as well as the GSE24551 patients (P=1.30×10^−2^ for stage II group; P= 6.97×10^−2^ for stage III group; [Fig. 8C and D](#f8-ijmm-42-01-0368){ref-type="fig"}) and GSE103479 patients (P=1.76×10^−2^ for stage II group; P=1.37×10^−2^ for stage III group; [Fig. 8E and F](#f8-ijmm-42-01-0368){ref-type="fig"}). In addition, in terms of OS survival in GSE103479 patients, the module was independent of the patient age and the mutation of P53 (P=4.84×10^−2^ for patients aged \>65 years; P=1.52×10^−2^ for the P53 mutated group; [Fig. 8G and H](#f8-ijmm-42-01-0368){ref-type="fig"}). Based on these data, it is concluded that the 14-inflammatory-gene-module is a strong prognostic indicator for CRC.

Discussion
==========

Inflammatory genes serve a key role in cell-cell communication, and dysfunctional inflammatory response can cause various diseases, including cancer. Thus, deciphering the inflammation-mediated mechanisms in CRC can provide opportunities for the early detection and treatment of CRC. A variety of inflammation-associated genes in CRC have been previously studied. For instance, Hickish *et al* ([@b45-ijmm-42-01-0368]) revealed that *MABp1* was associated with an antitumor activity and relief of debilitating symptoms in patients with advanced CRC. Foersch *et al* ([@b46-ijmm-42-01-0368]) reported that inhibition of VEGFR2 signaling led to senescence of human CRC, which may improve the CRC patient survival in clinical practice. Zhu *et al* ([@b47-ijmm-42-01-0368]) also suggested that *STING* mediated protection against colorectal tumorigenesis by participating in intestinal inflammation.

In the present study, a systematical analysis on the inflammatory genes in CRC was performed, developing an integrated network-based strategy to construct and identify the inflammation-associated networks and modules. The current study built two networks, namely IRNN and IRDN, with inflammatory genes in the IRNN closely interacting with cancer genes, and genes in the IRDN enriched in numerous cancer-associated functions and pathways. These inflammatory genes may modulate the communication between cancer and normal cells. In addition, the current study highlighted the importance of inflammatory genes in the prognosis of CRC through the identification of a 14-inflammatory-gene-module, which was further validated by three independent datasets, providing a novel insight for CRC diagnosis and therapy.

Notably, the top six hub nodes in IRNN were all inflammatory genes, including EP300, which encodes the E1A-binding protein p300 and is important in the processes of cell proliferation and differentiation. The frame-shift mutations of EP300 have been reported to contribute to cancer pathogenesis by deregulating E1A-binding protein p300-mediated functions ([@b48-ijmm-42-01-0368]). Furthermore, the tyrosine kinases of the SRC family participate in oncogenic signaling in advanced CRC, which is crucial in the progression of CRC ([@b49-ijmm-42-01-0368]). The CBP protein (encoded by CREBBP), together with p300, may influence colonic cell physiology by affecting Wnt signaling, as well as affect colonic tumorigenesis and stem cell pluripotency ([@b50-ijmm-42-01-0368]). In addition, Ding *et al* ([@b51-ijmm-42-01-0368]) observed that Grb2-associated binder 2 (Gab2) promoted intestinal tumor metastasis by inducing epithelial-to-mesenchymal transition through the MEK/ERK/MMP pathway, which indicated that Gab2 may function as a novel prognostic factor for CRC patients. Additionally, with the immunohistochemistry study, researchers have found that MAPK is highly expressed and extremely active in colorectal cells and can be a therapeutically relevant target in inflammatory bowel disease ([@b52-ijmm-42-01-0368],[@b53-ijmm-42-01-0368]).

In conclusion, although the inflammation-associated genes and modules should be confirmed by further experimental validations, the present study indeed provided a new direction for the exploration of the genesis and development of CRC using two inflammation-mediated gene networks. Furthermore, a 14-inflammatory-gene-module with prognostic potential was identified.
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![Properties of the IRNN. (A) The global IRNN and (B) the degree distribution of the nodes in the IRNN are shown. IRNN, inflammation-related neighbor network; DEG, differentially expressed gene.](IJMM-42-01-0368-g00){#f1-ijmm-42-01-0368}

![Comparison analysis of topological properties of inflammatory genes and other mRNAs in the IRNN. Box plot of the (A) degree, (B) BC and (C) CC of inflammatory genes and other nodes in the IRNN. (D) Box plot of BC of hub nodes and inflammatory genes in IRNN. (E) Box plot of BC of hub nodes and DEGs in IRNN. IRNN, inflammation-related neighbor network; DEG, differentially expressed gene; BC, betweenness centrality; CC, closeness centrality.](IJMM-42-01-0368-g01){#f2-ijmm-42-01-0368}

![Top six inflammatory genes ranked in terms of the gene degree, including EP300, SRC, CREBBP, GRB2, MAPK1 and FYN. DEG, differentially expressed gene.](IJMM-42-01-0368-g02){#f3-ijmm-42-01-0368}

![Properties of the IRDN. (A) The global IRDN is shown, and the size of the sphere represents the degree of the gene. (B) The degree distribution of mRNAs in the IRDN. IRDN, inflammation-related DEG network; DEG, differentially expressed gene.](IJMM-42-01-0368-g03){#f4-ijmm-42-01-0368}

![(A) Functional enrichment map of GO_BP_FAT terms. Each node represented a GO term, which was grouped and annotated by GO similarity. Each edge represented whether there was a shared gene between two GO terms. Node size represented the number of genes in the GO term. (B) Significantly enriched KEGG pathways of mRNAs in the IRDN. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; IRDN, inflammation-related DEG network; DEG, differentially expressed gene.](IJMM-42-01-0368-g04){#f5-ijmm-42-01-0368}

![Overview of 14-inflammatory-gene-module and its prognostic ability in assessing the clinical outcome of the training set colorectal cancer patients. (A) Overview of 14-inflammatory-gene-module, with the size of the sphere depicting the degree of the gene. (B) Kaplan-Meier survival curves for disease-free survival of patients in the training set GSE24550 with high- and low-risk scores. The P-value was calculated using the log-rank test. (C) Risk score analysis of the module in GSE24550. (D) ROC curve analysis and the AUC indicating the sensitivity and specificity of the module for survival prediction in the GSE24550 dataset. DFS, disease-free survival; ROC, receiver operating characteristic; AUC, area under the ROC curve.](IJMM-42-01-0368-g05){#f6-ijmm-42-01-0368}

![Survival curves and risk score analyses of the 14-inflammatory-gene-module in three independent datasets. Kaplan-Meier survival curves for DFS of patients with high- and low-risk scores in the (A) GSE24549, (B) GSE24551 and (C) GSE103497 datasets. Log-rank test was used to calculate the P-values. Risk score analysis of the module in the patients of the (D) GSE24549, (E) GSE24551 and (F) GSE103497 datasets. ROC curve analysis and AUC value indicating the sensitivity and specificity of the module for survival prediction in the (G) GSE24549, (H) GSE24551 and (I) GSE103497 datasets. DFS, disease-free survival; ROC, receiver operating characteristic; AUC, area under the ROC curve.](IJMM-42-01-0368-g06){#f7-ijmm-42-01-0368}

![Stratification analysis of independent datasets based on the stage. Kaplan-Meier survival curves of patients stratified by stage based on the 14-inflammatory-gene-module are shown for patients in the three datasets. (A) Stage II (n=46) and (B) stage III (n=37) CRC patients DFSin GSE24549; (C) stage II (n=90) and (D) stage III (n=70) CRC patients DFS in GSE24551; (E) stage II (n=83) and (F) stage III (n=72) CRC patients OS in GSE103479. In addition, (G) Kaplan-Meier OS curves of patients (n=102) in the GSE103479 dataset stratified by age (\>65 years) based on the 14-inflammatory-gene-module are displayed. (H) Kaplan-Meier OS curves of patients (n=78) in the GSE103479 dataset stratified by P53 mutation based on the 14-inflammatory-gene-module are presented. DFS, disease-free survival; OS, overall survival.](IJMM-42-01-0368-g07){#f8-ijmm-42-01-0368}

###### 

Clinical features of all CRC patients included in this study.

  Characteristic    GSE24550 (n=77)   GSE24549 (n=83)   GSE24551 (n=160)   GSE102479 (n=155)
  ----------------- ----------------- ----------------- ------------------ -------------------
  Stage, no. (%)                                                           
   II               44 (57.1)         46 (55.4)         90 (56.2)          83 (53.5)
   III              33 (42.9)         37 (44.6)         70 (43.8)          72 (46.5)
  Age, no. (%)                                                             
   ≤65              n/a               n/a               n/a                51 (32.9)
   \>65             n/a               n/a               n/a                102 (56.8)
  Gender, no. (%)                                                          
   Male             n/a               n/a               n/a                87 (56.1)
   Female           n/a               n/a               n/a                68 (43.9)
  BRAF mutation                                                            
   WT               n/a               n/a               n/a                122 (78.7)
   MT               n/a               n/a               n/a                15 (9.7)
  KRAS mutation                                                            
   WT               n/a               n/a               n/a                83 (53.5)
   MT               n/a               n/a               n/a                54 (34.8)
  P53 mutation                                                             
   WT               n/a               n/a               n/a                59 (38.1)
   MT               n/a               n/a               n/a                78 (50.3)

WT, wild type; MT, mutation type; n/a, not available.

###### 

Gene Expression Omnibus microarray datasets used in the present study.

  Datasets    Platform         Number of patients   Overall type   No. of tumor samples   No. of normal samples
  ----------- ---------------- -------------------- -------------- ---------------------- -----------------------
  GSE24550    HuEx-1_0-st      90                   DFS            77                     13
  GSE24549    HuEx-1_0-st      83                   DFS            83                     0
  GSE24551    HuEx-1_0-st      173                  DFS            160                    13
  GSE103497   ADXECv1a520743   156                  OS             156                    0

DFS, disease-free survival; OS, overall survival.

###### 

Univariate and multivariate Cox regression analysis of the module gene signature and disease-free survival of colorectal cancer patients in the training and test Gene Expression Omnibus datasets.

  Variables            Univariate model   Multivariate model                                 
  -------------------- ------------------ -------------------- --------- ------ ------------ ---------
  GSE24550 (DFS)                                                                             
   Module risk score   2.17               1.42--3.31           \<0.001   2.13   1.36--3.33   0.001
   Stage               1.77               0.72--4.35           0.216     1.12   0.43--2.90   0.817
  GSE24549 (DFS)                                                                             
   Module risk score   1.28               0.99--1.66           0.052     1.24   0.97--1.57   0.080
   Stage               2.02               1.11--3.71           0.022     1.93   1.05--3.56   0.034
  GSE24551 (DFS)                                                                             
   Module risk score   1.88               1.42--2.47           \<0.001   1.76   1.34--2.32   \<0.001
   Stage               1.97               1.19--3.25           0.008     1.61   0.96--2.70   0.069
  GSE103479 (OS)                                                                             
   Module risk score   2.13               1.24--3.64           0.006     1.58   0.92--2.70   0.094
   Stage               2.18               1.30--3.67           0.003     2.37   1.34--4.21   0.003
   Age                 1.06               1.03--1.09           \<0.001   1.05   1.02--1.09   0.001
   Gender              0.97               0.59--1.62           0.919     1.26   0.71--2.26   0.428
   BRAF mutation       1.91               0.90--4.07           0.091     1.17   0.50--2.78   0.714
   KRAS mutation       0.87               0.51--1.51           0.629     0.97   0.53--1.77   0.913
   P53 mutation        0.57               0.33--0.98           0.041     0.68   0.39--1.19   0.173

HR, hazard ratio; CI, confidence interval; DFS, disease-free survival; OS, overall survival.
